Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...

Aristada (aripiprazole lauroxil) is a prescription drug that’s used to treat schizophrenia. Aristada is given by a healthcare professional as an injection into a muscle. Aristada is used as a ...

ABILIFY Injection, an injectable form of ABILIFY for intramuscular use, provides healthcare professionals with the first ready-to-use single dose vial (9.75 mg/1.3 mL) of an atypical antipsychotic to ...

ABILIFY MAINTENA® (aripiprazole). Please see IMPORTANT SAFETY INFORMATION, including BOXED WARNING for INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS, for ABILIFY ASIMTUFII ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable ...